Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 7/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425847 | 0.84 | MAPK1 (0.38) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL11989033 | 0.84 | MAPK1 (0.38) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL23102801 | 0.84 | MAPK1 (0.38) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL23132331 | 0.81 | PIK3CD (0.38) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL26326345 | 0.81 | PIK3CD (0.38) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL23133625 | 0.81 | MAPK1 (0.35) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL23109027 | 0.81 | MAPK1 (0.35) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL26122493 | 0.79 | LMNA (0.35) | MAPK1BRD4BRD2 | |
| SCHEMBL24852411 | 0.78 | BRD4 (0.38) | MAPK1BRD4BRD2PIK3CDTACR1 | |
| SCHEMBL17981943 | 0.75 | BRD4 (0.34) | BRD4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| WO-2016130396-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, DNMT1 | MAPK1 3060/4885BRD4 1032/4885BRD2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.